Founded in late 2022, Conexeu Sciences Inc. is advancing regenerative medicine through its patented bioregenerative extracellular matrix platform. Emerging from over a decade of university research, the Company has a thermosensitive extracellular matrix that transitions from liquid to gel at body temperature, forming a biomimetic scaffold that supports organized tissue formation. With patents across the U.S., E.U., Japan, and Australia, and additional filings pending globally, Conexeu’s CXU™ platform offers transformative potential across multi-billion-dollar markets.

‍

At the forefront of Conexeu’s portfolio is Ten Minute Tissue™, an extracellular matrix (ECM) that remains fluid at room temperature and gels at ~37°C. This unique scaffold promotes cell migration, proliferation, differentiation, and new tissue formation, enabling seamless integration into host tissue. Scientifically proven in pre-clinical studies, Ten Minute Tissue™ demonstrated improved healing dynamics and a low inflammatory profile.